# Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly

Source: https://onco.cc/trials/nct00600886/  
OnCo record `nct00600886` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pasireotide and Somatostatin analogues in Pituitary tumours, run by Novartis Pharmaceuticals, completed.

## Summary

Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly is a phase 3 interventional study registered as NCT00600886 by Novartis Pharmaceuticals, with 358 participants recorded, started 2008-02-11 and reaching its primary completion in 2016-03-11. Interventions recorded: Pasireotide, Octreotide. Conditions recorded: Acromegaly.

Linked to the drug Pasireotide because the registry names it among its interventions and Pituitary tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00600886
- Phase: 3
- Setting: A Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs. Octreotide LAR in Patients With Active Acromegaly
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 358

## Sources

- ClinicalTrials.gov NCT00600886: https://clinicaltrials.gov/study/NCT00600886

## Connected records

- cancers: [Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma](https://onco.cc/cancers/pituitary-tumours/)
- drugs: [Pasireotide](https://onco.cc/drugs/pasireotide/), [Somatostatin analogues (octreotide, lanreotide)](https://onco.cc/drugs/octreotide-lanreotide/)

---
JSON: https://onco.cc/api/v1/entities/nct00600886.json